 Home > Active Ingredient News > Antitumor Therapy > NEJM: Post-cytoreductive chemotherapy can significantly improve the prognosis of patients with recurrent ovarian cancer

NEJM: Post-cytoreductive chemotherapy can significantly improve the prognosis of patients with recurrent ovarian cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

relugolix prostate cancer

red clover cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The main treatment for patients with ovarian cancer is surgical resection, followed by combined chemotherapy with carboplatin and paclitaxel
.

Recent studies have found that additional systemic therapy with bevacizumab or PARP inhibitors can improve patient progression-free survival

Ovarian cancer Recently researchers evaluated the clinical significance of secondary cytoreductive surgery for recurrent ovarian cancer patients

Patients with recurrent ovarian cancer participated in the study.
The patients received platinum-free chemotherapy for the first recurrence after at least 6 months, and randomly received two cytoreductive surgery (operation group) or control (platinum chemotherapy alone), followed by platinum chemotherapy
.

The patient's AGO score was positive, the ECOG score was 0, the ascites was less than 500 mL, and the lesion was completely resected during the first operation

407 patients participated in the study, of which 206 patients received cytoreductive surgery combined with chemotherapy, and 201 patients received chemotherapy alone
.

75.

The median overall survival of the surgical group was 53.

The surgery group has more advantages in both progression-free survival and overall survival

The surgery group has more advantages in both progression-free survival and overall survival.

For patients with recurrent ovarian cancer, compared with chemotherapy alone, postoperative cytoreductive chemotherapy can significantly prolong the overall survival of patients.

Philipp Harter et al.

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.